What Has Been The Historical And Current Growth Of The Esophageal Cancer Market?
The esophageal cancer market has seen considerable growth due to a variety of factors.
•The market size for esophageal cancer has seen robust growth in the past few years. It is projected to rise from $1.39 billion in 2024 to $1.52 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%.
Factors contributing to this growth during the historic period include a rise in cancer cases, enhancement in healthcare infrastructure, an increase in alcohol intake, a surge in demand for preventive healthcare solutions, and a higher prevalence of esophageal adenocarcinoma.
What Is The Forecast For The Esophageal Cancer Market By 2029?
The esophageal cancer market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to experience substantial expansion in the coming years, the esophageal cancer market is projected to reach up to $2.16 billion by 2029, with a compound annual growth rate (CAGR) of 9.3%.
The upsurge during the predicted timeframe can be ascribed to the escalated occurrences of esophageal cancer, an accelerating comprehension of healthcare among the public, enhancements in the healthcare infrastructure and chronic indulgence in smoking and alcohol, and the increasing cases of esophageal adenocarcinoma. Foreseeable trends throughout the projection period encompass advancements in treatment alternatives, heightened investments in research and development, growing use of precision medicine, the emergence of targeted therapies, increased engagement in clinical trials, and collaborations among academia, pharmaceutical companies, and health institutions.
Which Drivers Are Accelerating Growth In The Esophageal Cancer Market?
The growth of the esophageal cancer market is likely to be fueled by a growing number of esophageal cancer cases. This malignancy affects the esophagus, a tube-like structure that leads from the throat to the stomach. As the occurrence of esophageal cancer escalates, greater demand is anticipated for diagnostic procedures such as endoscopy, imaging tests, and biopsies, needed to identify and verify the disease. For example, the American Cancer Society, a United States-based professional organization, revealed that esophageal cancer caused 16,120 fatalities in 2023, and it anticipates this figure climbing to 16,130 in 2024. Therefore, the increasing prevalence of esophageal cancer is anticipated to boost the esophageal cancer market's expansion.
What Are The Core Segments Of The Global Esophageal Cancer Market?
The esophageal cancer market covered in this report is segmented –
1) By Type: Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Other Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By Esophageal Squamous-Cell Carcinoma: Localized Squamous-Cell Carcinoma, Advanced Squamous-Cell Carcinoma
2) By Esophageal Adenocarcinoma: Localized Adenocarcinoma, Advanced Adenocarcinoma
3) By Other Types: Neuroendocrine Tumors, Sarcomas, Mixed Cell Type Carcinomas
Pre-Book The Esophageal Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Esophageal Cancer Market Size?
The rise in new drug approvals is a significant trend being observed in the esophageal cancer market. Principal corporations in the market for esophageal cancer are working towards getting new drug approvals to consolidate their standing and gain a competitive edge. For example, in May 2022, Bristol Myers Squibb, a pharmaceutical firm based in the US, was granted approval for its two products, Opdivo (nivolumab) (an injectable) and Opdivo plus Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA). These drugs are primarily geared towards treating individuals diagnosed with advanced or metastatic esophageal squamous cell carcinoma (ESCC). These approvals came after the completion of Phase 3 clinical trials, which showcased improved survival rates among patients who were administered these drugs.
Who Are the Key Players in the Esophageal Cancer Market?
Major companies operating in the esophageal cancer market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline Plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Servier Pharmaceuticals
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Otsuka Pharmaceutical Co. Ltd.
• Ipsen SA
• Dr. Reddy's Laboratories Ltd.
• Seagen Inc.
• Exelixis Inc.
• BeiGene Ltd.
• Clovis Oncology Inc.
• Aslan Pharmaceuticals Ltd.
What are the Regional Insights into the Esophageal Cancer Market?
North America was the largest region in the esophageal cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
